Regulus Therapeutics

Regulus, Alnylam and Isis Announce U.S. Allowance of Tuschl III Patent Application Covering miR-21

January 25, 2010

Business Wire 1/25/09 The newly allowed claims cover miR-21, a microRNA that has been linked to a variety of diseases, including cancer, fibrosis, and heart disease. The claims additionally encompass single-stranded and double-stranded antisense compounds complementary to miR-21. The allowance of this second Tuschl III patent in the U.S. extends the scope of this patent [...]

Read the full article →

Upcoming Webcast – MicroRNA: The Year in Review

December 9, 2009

CARLSBAD, Calif., Dec. 9 /PRNewswire/ — Regulus Therapeutics Inc. will host an educational Webinar featuring a discussion with leading microRNA scientists: Tom Tuschl, Ph.D. Professor at Rockefeller University and Markus Stoffel, M.D., Ph.D. Professor at the Swiss Federal Institute of Technology. Dr. Tuschl will discuss the discovery of microRNA and its role as a master [...]

Read the full article →

Alnylam Pharmaceuticals & Regulus Therapeutics in the News

November 12, 2009

11/12/09 – CAMBRIDGE, Mass.–( Business Wire)–Alnylam Pharmaceuticals, Inc. an RNAi therapeutics company, today announced that it will webcast its upcoming R&D Day live on the “Investors” section of the company’s website at www.alnylam.com. Alnylam’s R&D Day will be held on Thursday, November 12, 2009 from 8:30 a.m. to 12:00 p.m. ET Alnylam scientists and management [...]

Read the full article →

Next Entries →